IntelliCap Oral Drug Delivery System Wins European Innovation Award
News Nov 20, 2014
The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.
As Medimetrics CEO Olaf Weiner explained: “We are delighted to win this award, in recognition of the unique capabilities of the technology behind our drug delivery systems. The use of IntelliCap will help deliver a revolution in healthcare which both saves costs and improves the outcomes for patients.”
The IntelliCap system was introduced into the market in 2011. An increasing number of pharma companies are using this powerful tool in the early-stage development and life cycle management of drugs. This unique, interactive device enables personalization of medications and treatments, empowering scientists to establish quickly the effective medication dose and delivery requirements. This reduces the risk of failure in expensive, late stage clinical trials, due to lack of safety or efficacy.
While the IntelliCap system is applied to speed the development of new products, the technology’s strength is its ability to enable the development of other pioneering products.
As Dr Weiner added: “The spirit of the award was to recognize the potential of the IntelliCap technology. Its ability to adapt and personalize during delivery will help usher in an era of smart pharmaceuticals to the benefit of patients.”
An early example is in the field of women’s health. LiGalli, a pioneering Dutch company led by Dr. Willem de Laat, is integrating the technology into a novel vaginal drug delivery system that enables new therapies.
In another example, IntelliCap technology creates a means of sampling and mapping content from the small intestine to identify its microbiological composition, in a non-invasive way. The mapping process will provide novel insights into how certain foods and also therapeutic agents might react in the gut and so affect our health.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018